Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

≈